Close Menu

More articles about Molecular Diagnostics

Illumina said it plans to "vigorously defend" the deal and oppose the FTC, which previously helped scuttle Illumina's proposed acquisition of Pacific Biosciences.

The 30-minute test can be used on samples from males and females in settings operating under a CLIA certificate of waiver.

Eurofins said its new multiplex PCR kit could be impactful for countries looking to gain control of disease clusters triggered by SARS-CoV-2 variants.

A Dutch province has awarded an unspecified sum to the Netherlands-based firms to combine their technologies for TCR and BCR repertoire sequencing and analysis.

Osang previously granted nonexclusive US distribution rights to the PCR-based test to SG Blocks and has a manufacturing arrangement for the test with Nexus Dx.

Concentric by Ginkgo has been partnering with labs across the US in more than 15 states to run testing for schools offering in-person education.

The firm's fourth quarter revenues included $18.3 million in commercial test revenue, of which $17.6 million was attributable to COVID-19 tests.

Amazon said that it will use its test for employees and other individuals who enter its facilities as part of its COVID-19 preparedness and response program.

Visby's single-use, fully integrated assay is designed to detect SARS-CoV-2 nucleic acid in samples collected either by a healthcare provider or self-collected.

The Korean molecular diagnostics firm, a spinoff from genomic services provider Macrogen, also announced plans for an IPO early next year.

Before launching its COVID-19 test, which generated most of Co-Diagnostics' revenues in 2020, the firm's sales primarily came from mosquito-borne virus testing.

The labs will provide testing for K-12 schools by testing each consenting person in a classroom as one pool.

For the year ended Dec. 31, 2020, the firm reported revenues of $8.5 million compared to $19.2 million in 2019, beating the Wall Street estimate of $8.3 million. 

The company's full-year revenues were $4.2 million, up 20 percent from the year-ago quarter.

The results represent a significant improvement over currently used screening tools and are spurring renewed LDT commercialization and regulatory submission efforts.

The company reported RMB133.9 million (US$20.5 million) for the quarter, up from RMB102.9 million in the same period of 2019.

The firm said that due to a negative coverage decision and capital constraints, it is evaluating options including a sale by a public takeover or an asset deal.

The automated sample-to-answer platform allows for a variety of assay types to be run simultaneously, such as molecular, immunochemistry, and cytometry tests.

The company is also working on a new Saphyr system that will have 14 times higher throughput than the current one, which can analyze 5,000 human genomes per year.

Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.


NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.